MetaVia Inc. (NASDAQ:MTVA) — Market Cap & Net Worth
Market Cap & Net Worth: MetaVia Inc. (MTVA)
MetaVia Inc. (NASDAQ:MTVA) has a market capitalization of $10.67 Million ($10.67 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26993 globally and #5595 in its home market, demonstrating a -10.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MetaVia Inc.'s stock price $1.62 by its total outstanding shares 6588101 (6.59 Million). Also see MetaVia Inc. assets under control for a full breakdown of the balance sheet.
MetaVia Inc. Market Cap History: 2024 to 2026
MetaVia Inc.'s market capitalization history from 2024 to 2026. Data shows change from $13.37 Million to $10.67 Million (-22.37% CAGR). Also see MTVA cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
MetaVia Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #760 of 976 |
Weight: MetaVia Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MetaVia Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MetaVia Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MTVA live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MTVA by Market Capitalization
Companies near MetaVia Inc. in the global market cap rankings as of September 18, 2026. Review MetaVia Inc. tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to MetaVia Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
MetaVia Inc. Historical Marketcap From 2024 to 2026
Between 2024 and today, MetaVia Inc.'s market cap moved from $13.37 Million to $ 10.67 Million, with a yearly change of -22.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.67 Million | -80.76% |
| 2025 | $55.47 Million | +314.78% |
| 2024 | $13.37 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of MetaVia Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.67 Million USD |
| MoneyControl | $10.67 Million USD |
| MarketWatch | $10.67 Million USD |
| marketcap.company | $10.67 Million USD |
| Reuters | $10.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as … Read more